EUCTR2010-022380-35-GB进行中（未招募）不适用
A randomized, double-blind, placebo-controlled, multicenter, parallel-group, adaptive group-sequential phase II study, to determine the efficacy and safety of BT086 as an adjunctive treatment in severe community acquired pneumonia (sCAP) - CIGMA (Concentrated IgM for Application) Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Biotest AG
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent: • given by the patient or • a legal/authorised representative of the patient or • a waiver for written informed consent due to emergency situation, in compliance with all local legal requirements. 2. Male or female patients aged 18 years or older 3. Patient receiving adequate antibiotic treatment for pneumonia 4. Prior to endotracheal ventilation and therapy, the patient must have at least one of the following two signs of inflammation: • Fever/Hypothermia Fever defined as an oral, tympanic, oesophageal, or vesical temperature of >38 C, or rectal temperature of >38.5 C, or hypothermia (rectal temperature <35.5 C) (measurement with temperature probe or device) or • White blood cell (WBC) count >10,000/mm³ or WBC <4,500/mm³ 5. Patient must have at least one of the following signs and symptoms of pneumonia: • New or increased cough • Production of purulent sputum or change in sputum characteristics • Dyspnoea or tachypnoea (respiratory rate >20 breaths/minute) • Pleuritic chest pain • Auscultatory findings on pulmonary examination of rales and/or crackles and/or evidence of pulmonary consolidation (e.g. dullness on percussion, bronchial breath sounds, or egophony) 6. Radiological (or other imaging technique) evidence of (an) infiltrate(s) consistent with bacterial pneumonia 7. Pneumonia has been acquired outside the hospital. In hospital-admitted patients, pneumonia has been diagnosed a maximum of 72 hours after admission. Patients from nursing homes or similar institutions are eligible. 8. Major sCAP criterion: need for endotracheal ventilation 9. Treatment of patient with BT086 must start within 12 hours but not earlier than 1 hour after start of endotracheal ventilation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1. For incapacitated patients: any indication that the patient’s presumed will would be against inclusion in the trial 2. Patients with suspected hospital-acquired pneumonia 3. Severe lung diseases interfering with sCAP therapy e.g. patients with cystic fibrosis, 4. Patients receiving Xigris® (drotrecogin alfa, activated Protein C) or medications not approved for sCAP (e.g. Dornase alpha) are excluded from inclusion in the study 5. Patients on dialysis 6. Presence of other severe diseases impairing life expectancy (e.g. patients are not expected to survive 28 days given their pre-existing uncorrectable medical condition). 7. Patients unable to be treated due to obesity 8. Selective, absolute IgA deficiency with known antibodies to IgA 9. Patients with neutrophil count <1,000/mm³ or platelet count <50,000/mm³ 10. Pregnant or lactating women. A pregnancy test will be performed in all women aged <65 years and the result must be available at study inclusion. 11. Known relevant intolerance to immunoglobulins, vaccines or other substances of human origin 12. Participation in another interventional clinical trial within 30 days before entering the study or during the study, and/or previous participation in this study (participation in non-interventional trials is allowed).
研究者
相似试验
进行中（未招募）
1 期
Study on the safety of the drug runcaciguat and how well it works when given at the highest dose as tolerated by the individual patient whose kidneys are not working properly and suffering at the same time from a disease of the heart and the blood vessels and high blood sugarTreatment of cardiovascular and renal disease in patients with chronic kidney diseaseMedDRA version: 21.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2019-003297-53-ESBayer AG432
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2500 mg/d combined with risperidone in the treatment of manic episodes of bipolar I disorder over 6 weeksBipolar I disorder, manic and mixed episodesEUCTR2004-000113-18-HUovartis Hungaria Kft.430
进行中（未招募）
1 期
Phase 2b dose-ranging study of ALX-0171 in infants and young children hospitalized for RSV lower respiratory tract infectioRSV lower respiratory tract infectionMedDRA version: 20.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-001651-49-SKAblynx NV180
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapyDiffuse Large B-Cell LymphomaMedDRA version: 19.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000498-40-HUovartis Pharma Services AG487
进行中（未招募）
1 期
Safety and efficacy study in patients with moderate to severe nail psoriasisModerate to severe nail psoriasisMedDRA version: 18.0Level: PTClassification code 10028703Term: Nail psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-005413-40-BEovartis Pharma Services AG195